Literature DB >> 3289771

Cyclosporine-pancuronium interaction in a patient with a renal allograft.

E Crosby1, J A Robblee.   

Abstract

A case is described of a 54-year-old 55 kg patient who presented for clipping of a middle cerebral aneurysm two years after a successful renal allograft. Immunosuppression was maintained with azathioprine 100 mg daily, cyclosporine 300 mg daily and prednisone 10 mg daily. The patient had chronic hypertension controlled with nifedipine 40 mg daily and furosemide 20 mg daily. The cyclosporine level taken on the morning of surgery was 166 micrograms.L-1. Induction of anaesthesia consisted of fentanyl 350 micrograms, thiopentone 125 mg and pancuronium 5.5 mg. Anaesthesia was maintained with nitrous oxide 70 per cent in oxygen and isoflurane 0.5-1.5 per cent. No additional doses of pancuronium were given during the four hour surgical procedure. At the end of surgery, four twitches were present with train-of-four stimulation, but evidence of residual muscle paralysis was present. Residual neuromuscular blockade was reversed with atropine 1.2 mg and neostigmine 2.5 mg. Residual paralysis was present in the Recovery Room and edrophonium 10 mg was given prior to extubation. Clinical testing demonstrated adequate reversal of neuromuscular blockade. Twenty minutes following extubation, increasing respiratory distress was noted. There was clinical evidence of muscle paralysis. The patient was re-intubated. It is proposed that cyclosporine potentiated the pancuronium blockade producing prolonged neuromuscular relaxation resulting in residual paralysis following surgery. The potential interactions of cyclosporine and muscle relaxants deserve further study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289771     DOI: 10.1007/bf03010635

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

1.  Residual curarization in the recovery room.

Authors:  J Viby-Mogensen; B C Jørgensen; H Ording
Journal:  Anesthesiology       Date:  1979-06       Impact factor: 7.892

2.  Pharmacokinetics of pancuronium in patients with normal and impaired renal function.

Authors:  K McLeod; M J Watson; M D Rawlins
Journal:  Br J Anaesth       Date:  1976-04       Impact factor: 9.166

3.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

Review 4.  Cyclosporin A--usefulness, risks and mechanism of action.

Authors:  S Britton; R Palacios
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Cyclosporin A in cadaveric organ transplantation.

Authors:  R Y Calne; D J White; D B Evans; S Thiru; R G Henderson; D V Hamilton; K Rolles; P McMaster; T J Duffy; B R MacDougall; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

6.  Onset time for alcuronium and pancuronium after cremophor-containing anaesthetics.

Authors:  L Gramstad; P Lilleaasen; B Minsaas
Journal:  Acta Anaesthesiol Scand       Date:  1981-12       Impact factor: 2.105

7.  Interaction of cyclosporin and its solvent, Cremophor, with atracurium and vecuronium. Studies in the cat.

Authors:  L Gramstad; J A Gjerløw; E S Hysing; H E Rugstad
Journal:  Br J Anaesth       Date:  1986-10       Impact factor: 9.166

  7 in total
  6 in total

1.  Cyclosporine-vecuronium interaction.

Authors:  G G Wood
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

2.  Does cyclosporine affect the duration of action of vecuronium in renal transplant recipients?

Authors:  Koichi Takita; Yukiko Goda; Osamu Kemmotsu; Atsushi Okuyama; Tadayoshi Ito; Hiroshi Sakamoto; Hideyuki Mashio; Hiroshi Kawahigashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

3.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

Review 4.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 6.  Approach to neuromuscular disorders in the intensive care unit.

Authors:  Kenneth C Gorson
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.